{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:17:26Z","timestamp":1790198246254,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijo.ijo_382_19","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T07:46:11Z","timestamp":1571730371000},"page":"1800","source":"Crossref","is-referenced-by-count":18,"title":["Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion\u2013related macular edema: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.4103","volume":"67","author":[{"given":"Jianfeng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.269632-1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"International eye disease consortium: The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(14)70001-7","article-title":"Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics","author":"Hayreh","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0161-6420(86)33651-0","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion","author":"Finkelstein","year":"1986","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-4","first-page":"1024","article-title":"Grid laser treatment in macular branch retinal vein occlusion","author":"Parodi","year":"39;s","journal-title":"Graefe"},{"key":"key-10.4103\/0301-4738.269632-5","first-page":"1425","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: The Central Vein Occlusion Study Group M report","author":"The","year":"1995","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-6","first-page":"1434","article-title":"A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Vein Occlusion Study Group N report","author":"The","year":"1995","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: A prospective study","author":"Kriechbaum","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-8","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-Year results from the phase 3 COPERNICUS study","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-Month outcomes of a phase III study","author":"Brown","year":"2011","journal-title":"Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-11","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-015-0017-z","article-title":"Ranibizumab for macular edema secondary to retinal vein occlusion: A meta-analysis of dose effects and comparison with no anti-VEGF treatment","author":"Song","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/jop.2013.0023","article-title":"Bevacizumab for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis","author":"Lu","year":"2013","journal-title":"JOcul Pharmacol Ther"},{"key":"key-10.4103\/0301-4738.269632-14","unstructured":"Novartis. Extension study to compare long-term efficacy and safety of ranibizumab intravitreal injections versus dexamethasone intravitreal implant in patients with RVO. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01580020?term=NCT01580020.& rank=1. 2016. [Last accessed on 2018 Aug 25]."},{"key":"key-10.4103\/0301-4738.269632-15","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2147\/OPTH.S144688","article-title":"Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naive retinal vein occlusion related macular edema","author":"Laine","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000350812","article-title":"Prospective pilot study: Efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion","author":"Guignier","year":"2013","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.269632-17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ceo.12311","article-title":"Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: Aprospective randomized comparison","author":"Gado","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-18","unstructured":"Novartis. Efficacy and safety of ranibizumab intravitreal injections versus dexamethasone intravitreal implant in patients with central retinal vein occlusion COMRADE-C (CRVO). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01396083?term =NCT01396083&rank=1. [Last accessed on 2019 May 24]."},{"key":"key-10.4103\/0301-4738.269632-19","unstructured":"Allergan. Safety and Efficacy Study of Ozurdex\u00ae Compared to Lucentis\u00ae in Patients With Branch Retinal Vein Occlusion. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01427751?term =NCT01427751&rank=1. 2016. [Last accessed on 2016 Jan 19]."},{"key":"key-10.4103\/0301-4738.269632-20","unstructured":"Novartis. Efficacy and safety of ranibizumab intravitreal injections versus dexamethasone intravitreal implant in patients with branch retinal vein occlusion (BRVO) (COMRADE-B). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01396057?term=NCT01396057&rank=1. 2014. [Last accessed on 2019 May 24]."},{"key":"key-10.4103\/0301-4738.269632-21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European label study","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-22","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)","author":"Hattenbach","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: One-year results of the phase 3 GALILEO study","author":"Korobelnik","year":"2014","journal-title":"Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-24","first-page":"1257","article-title":"Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex\u00ae) in its treatment","author":"Garweg","year":"39;s","journal-title":"Graefe"},{"key":"key-10.4103\/0301-4738.269632-25","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00417-018-4016-7","article-title":"Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: A3-year experience","author":"Blanc","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.4103\/0301-4738.269632-26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","article-title":"Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab","author":"Funk","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.269632-27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor a in intraocular vascular disease","author":"Miller","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-28","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1167\/iovs.17-23437","article-title":"Changes in retinal microvasculature and visual acuity after antivascular endothelial growth factor therapy in retinal vein occlusion","author":"Winegarner","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.269632-29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.269632-30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/jop.2017.0148","article-title":"A 5-Year follow-up study of the treatment of macular edema due to retinal vein occlusion using dexamethasone intravitreal implants","author":"Garay-Aramburu","year":"2018","journal-title":"JOcul Pharmacol Ther"},{"key":"key-10.4103\/0301-4738.269632-31","first-page":"627674","article-title":"Anti-VEGF therapy and the retina: An update","author":"Tah","year":"2015","journal-title":"JOphthalmol"},{"key":"key-10.4103\/0301-4738.269632-32","first-page":"70","article-title":"Management of macular edema due to central retinal vein occlusion 4 The role of aflibercept","author":"Rhoades","year":"2017","journal-title":"Taiwan J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/2211-5056","issn-type":"print"},{"key":"key-10.4103\/0301-4738.269632-33","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ophtha.2017.03.060","article-title":"Therapies for macular edema associated with branch retinal vein occlusion: A report by the American academy of ophthalmology","author":"Ehlers","year":"2017","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.269632-34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/17512433.2018.1507735","article-title":"Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: A systematic review and network meta-analysis","author":"Sangroongruangsri","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key-10.4103\/0301-4738.269632-35","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/09273948.2016.1184284","article-title":"Common and rare ocular side-effects of the dexamethasone implant","author":"Fassbender","year":"2017","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:58Z","timestamp":1786732498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_382_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"alternative-id":["269632"],"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_382_19","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}